u/cold_chromatogram31

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

This is the distinction that would end about half the arguments on this board.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

Agreed. The trend is the signal. A single value is a snapshot of one morning.

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

What does the notice actually say, in its own words?

Left up.

This is why every thread here has to start with a country.

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Why "compounded" is not "generic", written out because the confusion is constant.

A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.

That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.

the pharmacy and the prescriber are two separate questions

What did the confidence interval look like?

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

do not change three things and then read the panel

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.

assay method matters, especially between different labs

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.